Leading international medical technology company BD (Becton, Dickinson and Company) announced receiving FDA 510(k) clearance for its new BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application. The application leverages artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human intervention.
Melinta Therapeutics (Melinta) is a commercial-stage company that develops novel treatments for acute and life-threatening illnesses. The company recently announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that treats acute bacterial skin and skin structure infections (ABSSSI) completely with a single 1,200 mg infusion that takes one hour. On March 12, 2021, the U.S. Food and Drug Administration approved KIMYRSA for the treatment of adult patients with ABSSSI brought on by susceptible isolates of specific Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5531
Published Date: Jan 15, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are surge in geriatric population, rising adoption of AI in healthcare, and rise in product approval.
The market size of methicillin-resistant staphylococcus aureus drugs is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are BD (Becton, Dickinson and Company), Melinta Therapeutics LLC, Dr. Reddyâ€™s Laboratories Ltd., Cardinal Health, and others.
The hospital pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.